Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2~* Relapsed or refractory FL after treatment with at least one prior chemoimmunotherapy regimen that included an anti-CD20 monoclonal antibody and for which no other more appropriate treatment option exists as determined by the investigator~* Histologically documented CD20-positive lymphoma as determined by the local laboratory~* Fluorodeoxyglucose-avid lymphoma (i.e., PET-positive lymphoma)~* At least one bi-dimensionally measurable lesion (\>1.5 cm in its largest dimension by CT scan or magnetic resonance imaging \[MRI\])~* Availability of a representative tumor specimen and the corresponding pathology report for retrospective central confirmation of the diagnosis of FL~* Agreement to comply with all local requirements of the lenalidomide risk minimization plan~* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use two adequate methods of contraception, including at least one method with a failure rate of \<1% per year, for at least 28 days prior to Day 1 of Cycle 1, during the treatment period (including periods of treatment interruption), and for at least 18 months after the last dose of study treatment~* For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures and agreement to refrain from donating sperm for at least 3 months after the last dose of study treatment~Exclusion Criteria:~* Grade 3b follicular lymphoma~* History of transformation of indolent disease to diffuse large B-cell lymphoma (DLBCL)~* Known CD20-negative status at relapse or progression~* Central nervous system lymphoma or leptomeningeal infiltration~* Prior allogeneic stem-cell transplantation (SCT)~* Completion of autologous SCT within 100 days prior to Day (D) 1 of Cycle (C) 1~* Prior standard or investigational anti-cancer therapy as specified in protocol~* History of resistance to lenalidomide or response duration of \<1 year~* Treatment with systemic immunosuppressive medications~* History of solid organ transplantation~* Clinically significant toxicity from prior therapy that has not resolved to Grade \<=2 (according to the National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI CTCAE\], v4.0) prior to Day 1 of Cycle 1~* History of erythema multiforme, Grade \>= 3 rash, or blistering following prior treatment with immunomodulatory derivatives such as thalidomide and lenalidomide~* Active bacterial, viral, fungal, or other infection~* Positive for hepatitis B surface antigen (HBsAg), total hepatitis B core antibody (HBcAb), or hepatitis C virus (HCV) antibody at screening~* Known history of HIV positive status~* History of progressive multifocal leukoencephalopathy~* History of autoimmune disease~* Contraindication to treatment for TE prophylaxis~* Grade \<= 2 neuropathy~* History of other malignancy that could affect compliance with the protocol or interpretation of results~* Evidence of any significant, uncontrolled concomitant disease~* Inadequate hematologic function (unless due to underlying lymphoma)~* Abnormal laboratory values (unless due to underlying lymphoma)~* Pregnant or lactating or intending to become pregnant during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Atezolizumab-G-lena 15mg (Type: EXPERIMENTAL): Participants were administered obinutuzumab, Atezolizumab, and 15 mg of Lenalidomide.
- Atezolizumab-G-lena 20mg (Type: EXPERIMENTAL): Participants were administered obinutuzumab, Atezolizumab, and 20 mg of Lenalidomide.

Based on this trial design, predict the completion outcome and termination type (if applicable).